Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 43,700 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Nov 02, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 24,782 | $2.52 | 363,546 | |
| Nov 02, 2020 | Director, Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 24,782 | $17.87 | 338,764 | |
| Nov 02, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 24,782 | -- | 35,436 | |
| Nov 02, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 23,975 | $5.96 | 864,888 | |
| Nov 02, 2020 | Director, Chairman & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 33,875 | $17.87 | 831,013 | |
| Nov 02, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 23,975 | -- | -- | |
| Nov 02, 2020 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 1,500 | $18.01 | 36,967 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.